[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Roy E. Weiss, M.D.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":12,"acronym":13,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":4,"maxAge":16,"enrollmentInfo":4,"targetDuration":4,"studyType":17,"phases":4,"briefSummary":18,"conditions":19,"keywords":4,"overallStatus":21,"whyStopped":4,"lastUpdateSubmitDate":22,"lastUpdatePostDateStruct":23,"startDateStruct":4,"completionDateStruct":4,"leadSponsor":26,"locationsCount":5},"100373505",false,"NCT04143295","Rescue of Infants With MCT8 Deficiency","DITPA","Inclusion Criteria\n\n* Genetic Confirmation: Male fetus or fetuses (including monozygotic twin pregnancies) must have a confirmed MCT8 gene mutation.\n* Family History: A previously born child or children with a severe, typical phenotype and an MCT8 gene mutation identical to that of the fetus.\n* Alternatively, the mother or a sister must have a relative with a known MCT8 defect.\n* Parental Decision: Parental refusal to terminate the pregnancy despite the diagnosis of MCT8 deficiency.\n* Compliance and Availability: Willingness of the parents to comply with all study procedures and ensure availability for the duration of the study.\n\nExclusion Criteria:\n\n• Pregnancy-Related Factors: Dizygotic (non-identical) twin pregnancy (unless only one fetus is confirmed with the MCT8 mutation, and the unaffected fetus will not be treated).\n\nParental decision to terminate the pregnancy.\n\n• Maternal Medical Conditions: Hyperthyroidism requiring treatment. Significant liver or kidney insufficiency. Congestive heart failure. Hyperemesis gravidarum unresponsive to treatment.\n\n* Significant cardiac conditions, including:\n* Atrial fibrillation or other arrhythmias.\n* Unstable angina.\n* Coronary heart disease.\n* Medications:\n\nCurrent use of sympathomimetic therapy. Anticoagulant therapy. Use of Cytochrome P450 2C9 (CYP2C9) inhibitors with a narrow therapeutic index.\n\n• Other Factors: Major illness or recent major surgery within four weeks of baseline visit 1, unrelated to MCT8 deficiency.","MALE","18 Years","EXPANDED_ACCESS","Monocarboxylate Transporter 8 (MCT8) deficiency (that is also known as Allan-Herndon-Dudley syndrome) is a rare X-linked inherited disorder of brain development that causes severe intellectual disability and problems with movement. This condition, which occurs almost exclusively in males, disrupts development from before birth.",[20],"Mct8 (Slc16A2)-Specific Thyroid Hormone Cell Transporter Deficiency","AVAILABLE","2025-12-03",{"date":24,"type":25},"2025-12-11","ACTUAL",{"name":27,"class":28},"Roy E. Weiss, M.D.","OTHER",""]